Revenue
2015
2016
2017
2018
2019
2022
2023
2024
2025
Enveric Biosciences, Inc. (ENVB)
Price$1.39Cached quote
Net income
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2020
2021
2022
2023
Total cash / debt
CashTotal debt
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | — | — | $39.9M | $43.0M | $48.6M | $36.1M | $20.3M | — | — | — | — | — |
| Gross profit | — | — | — | — | $0 | — | $8.2M | $9.0M | $10.2M | $6.9M | $6.9M | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | 20.42% | 20.89% | 21.07% | 19.17% | 33.91% | — | — | — | — | — |
| Research & development | $2.8M | $2.8M | $7.3M | $8.0M | $4.8M | $174,083 | — | — | — | $55,104 | — | — | — | — | — | — |
| Operating expenses | $8.8M | $9.6M | $16.4M | $27.4M | $64.6M | $5.6M | $14.5M | $16.1M | $21.1M | $12.3M | $7.7M | — | — | — | — | — |
| Operating income | −$8.8M | −$9.6M | −$16.4M | −$27.4M | −$64.6M | −$5.6M | −$2.3M | −$7.1M | −$10.9M | −$5.4M | −$793,982 | $32,811 | $27,211 | −$22,690 | −$31,395 | −$35,875 |
| Operating margin | — | — | — | — | — | — | −5.75% | −16.62% | −22.42% | −14.88% | −3.92% | — | — | — | — | — |
| EBITDA | −$8.6M | −$9.3M | −$16.1M | −$27.1M | −$64.0M | −$5.5M | −$31,237 | −$4.2M | −$7.7M | −$4.0M | −$627,774 | — | — | — | — | — |
| EBITDA margin | — | — | — | — | — | — | −0.08% | −9.87% | −15.80% | −11.12% | −3.10% | — | — | — | — | — |
| Net income | −$8.8M | −$9.6M | −$17.3M | −$18.5M | −$49.0M | −$6.9M | −$2.4M | −$16.9M | −$9.1M | −$2.8M | −$814,075 | −$33,644 | −$161 | −$24,621 | −$33,380 | −$39,441 |
| Net profit margin | — | — | — | — | — | — | −6.04% | −39.30% | −18.67% | −7.69% | −4.02% | — | — | — | — | — |
| Basic EPSper basic share | -$36.24 | -$228.48 | -$1,455.48 | -$2,340.00 | -$18,664.20 | -$10,710.00 | -$25,470.00 | -$184,230.00 | -$168,750.00 | -$47,250.00 | -$15,750.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$2,250.00 |
| Diluted EPSper diluted share | -$36.24 | -$228.48 | -$1,455.48 | -$2,340.00 | -$18,630.00 | -$10,710.00 | -$25,470.00 | -$184,230.00 | -$168,750.00 | -$47,250.00 | -$15,750.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$2,250.00 |
Owners
Reported shareholders
≈6.90%of listed shares
Tucker Joseph Edward271.48K shares · Jun 1, 2026
View holders
| Holder | % owned |
|---|---|
Tucker Joseph Edward | ≈6.90%271.48K shares |
Coveney Kevin Michael | ≈4.59%180.75K shares |
Sio Capital Management, LLC | 4.57%180K shares |
Ikarian Capital, LLC | 2.54%100K shares |
AdvisorShares Investments LLC | 0.90%35.42K shares |
RENAISSANCE TECHNOLOGIES LLC | 0.81%32.06K shares |
ARMISTICE CAPITAL, LLC | 0.81%32K shares |
BOOTHBAY FUND MANAGEMENT, LLC | 0.77%30.14K shares |
Facchini Peter J. | —27.76K shares |
PASQUALONE FRANK | ≈0.67%26.42K shares |
Schabacker Marcus | ≈0.67%26.42K shares |
Kegler George A. | ≈0.67%26.42K shares |
WEBB MICHAEL D | ≈0.67%26.42K shares |
DeWitt Sheila | ≈0.67%26.31K shares |
XTX Topco Ltd | 0.48%18.99K shares |
HRT FINANCIAL LP | 0.39%15.46K shares |
VANGUARD CAPITAL MANAGEMENT LLC | 0.38%14.91K shares |
CITADEL ADVISORS LLC | 0.35%13.97K shares |
StoneX Group Inc. | 0.30%11.81K shares |
GEODE CAPITAL MANAGEMENT, LLC | 0.30%11.79K shares |
Percentages use 3.94M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 4 ↗Updated Sep 29, 2026 · Quarterly data